KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBITDA Margin (2016 - 2026)

Medpace Holdings filings provide 12 years of EBITDA Margin readings, the most recent being 20.98% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 54.0% to 20.98% in Q1 2026 year-over-year; TTM through Mar 2026 was 22.04%, a 42.0% decrease, with the full-year FY2025 number at 22.22%, down 29.0% from a year prior.
  • EBITDA Margin hit 20.98% in Q1 2026 for Medpace Holdings, down from 22.61% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 24.7% in Q4 2024 to a low of 18.31% in Q2 2023.
  • Median EBITDA Margin over the past 5 years was 21.21% (2024), compared with a mean of 21.05%.
  • Biggest five-year swings in EBITDA Margin: tumbled -305bps in 2023 and later skyrocketed 589bps in 2024.
  • Medpace Holdings' EBITDA Margin stood at 20.68% in 2022, then fell by -9bps to 18.81% in 2023, then skyrocketed by 31bps to 24.7% in 2024, then fell by -8bps to 22.61% in 2025, then decreased by -7bps to 20.98% in 2026.
  • The last three reported values for EBITDA Margin were 20.98% (Q1 2026), 22.61% (Q4 2025), and 22.52% (Q3 2025) per Business Quant data.